Serum squamous cell carcinoma antigen-2 is a highly sensitive biomarker for atopic dermatitis in children
Sunday, March 4, 2018
South Hall A2 (Convention Center)
Toshiaki Kawano, MD, Mizuho Nagao, MD, PhD, Takao Fujisawa, MD FAAAAI, Hiroshi Odajima, MD,PhD, Shinichiro Inagaki, MD, PhD, Yukihiro Ohya, MD PhD, Yoshinori Azuma, Noriko Nomura, Kenji Izuhara, MD PhD
RATIONALE: Squamous cell carcinoma antigen (SCCA) was reported to be elevated in various inflammatory skin diseases including atopic dermatitis (AD). Since Th2 cytokines stimulate SCCA production in the skin tissue, possible utility of serum SCCA as a biomarker for AD has been suggested, but merely by single-center, small-scale studies.

METHODS: Multicenter prospective observational study to investigate the clinical significance of serum SCCA2 in children as a biomarker for AD was performed. Patients with AD younger than 16 and age-matched healthy children without any allergic disease were enrolled in the study. Severity of AD was evaluated by using the objective SCORAD (O-SCORAD). Serum levels of SCCA2 and TARC were measured with ELISA.

RESULTS: Totals of 176 patients with AD and 159 non-allergic healthy children were tested. Serum levels of SCCA2 and TARC were significantly correlated with O-SCORAD with Spearman’s correlation coefficients of 0.622 and 0491, respectively. According to improvement of the symptoms by a standard treatment with topical steroids and emollients, serum levels of SCCA2 and TARC were significantly reduced. ROC analysis to diagnose AD yielded AUC at 0.929 and 0.871, respectively. Both the markers in normal children were higher in young infants.

CONCLUSIONS: SCCA2 is a reliable biomarker for AD in children and may be superior to TARC.